French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) on Thursday announced positive results from the IRAKLIA phase 3 study evaluating Sarclisa administered subcutaneously (SC) via an on-body delivery system (OBDS) in combination with pomalidomide and dexamethasone for the treatment of relapsed or refractory multiple myeloma.
The study met its co-primary endpoints of non-inferior objective response rate (ORR) and observed concentration before dosing (C trough) at steady state compared to intravenous (IV) Sarclisa. Key secondary endpoints were also achieved.
IRAKLIA used Enable Injections' enFuse OBDS, designed for the subcutaneous administration of high-volume medicines.
Regulatory submissions for Sarclisa SC are planned for the United States and the European Union in the first half of 2025.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA